Avenue Therapeutics Net Worth
Avenue Therapeutics Net Worth Breakdown | ATXI |
Avenue Therapeutics Net Worth Analysis
Avenue Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Avenue Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Avenue Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Avenue Therapeutics' net worth analysis. One common approach is to calculate Avenue Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Avenue Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Avenue Therapeutics' net worth. This approach calculates the present value of Avenue Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Avenue Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Avenue Therapeutics' net worth. This involves comparing Avenue Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Avenue Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Avenue Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Avenue Therapeutics' net worth research are outlined below:
| Avenue Therapeutics generated a negative expected return over the last 90 days | |
| Avenue Therapeutics has high historical volatility and very poor performance | |
| Avenue Therapeutics may become a speculative penny stock | |
| Avenue Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (10.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Avenue Therapeutics currently holds about 890 K in cash with (9.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Avenue Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 25.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Herskowitz Neil of 2500 shares of Avenue Therapeutics at 3.99 subject to Rule 16b-3 |
Avenue Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Avenue Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Avenue Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Avenue Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Avenue Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Avenue Therapeutics backward and forwards among themselves. Avenue Therapeutics' institutional investor refers to the entity that pools money to purchase Avenue Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 7.9 K | Wells Fargo & Co | 2024-12-31 | 500 | Sbi Securities Co Ltd | 2024-12-31 | 9.0 | Jpmorgan Chase & Co | 2024-09-30 | 2.0 | Moss Adams Wealth Advisors Llc | 2024-12-31 | 0.0 | Armistice Capital, Llc | 2024-12-31 | 0.0 |
Follow Avenue Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.26 M.Market Cap |
|
Project Avenue Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (5.05) | (5.30) | |
| Return On Capital Employed | (25.57) | (24.29) | |
| Return On Assets | (5.05) | (5.30) | |
| Return On Equity | (7.54) | (7.17) |
When accessing Avenue Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Avenue Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Avenue Therapeutics' profitability and make more informed investment decisions.
Evaluate Avenue Therapeutics' management efficiency
Avenue Therapeutics has return on total asset (ROA) of (4.7194) % which means that it has lost $4.7194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.351) %, meaning that it created substantial loss on money invested by shareholders. Avenue Therapeutics' management efficiency ratios could be used to measure how well Avenue Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -5.3. The Avenue Therapeutics' current Return On Capital Employed is estimated to increase to -24.29. The current Total Assets is estimated to decrease to about 1.6 M. The current Net Tangible Assets is estimated to decrease to about 2.8 M| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.17 | 3.33 | |
| Tangible Book Value Per Share | 4.17 | 3.33 | |
| Enterprise Value Over EBITDA | (0.02) | (0.02) | |
| Price Book Value Ratio | 0.97 | 1.02 | |
| Enterprise Value Multiple | (0.02) | (0.02) | |
| Price Fair Value | 0.97 | 1.02 | |
| Enterprise Value | 6.6 B | 4.7 B |
The management strategies employed by Avenue Therapeutics' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avenue Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avenue Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avenue Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avenue Therapeutics time-series forecasting models is one of many Avenue Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Avenue Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Avenue Therapeutics Earnings per Share Projection vs Actual
Already Invested in Avenue Therapeutics?
The danger of trading Avenue Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Avenue Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Avenue Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Avenue Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Avenue Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avenue Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avenue Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avenue Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avenue Therapeutics. If investors know Avenue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avenue Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Avenue Therapeutics is measured differently than its book value, which is the value of Avenue that is recorded on the company's balance sheet. Investors also form their own opinion of Avenue Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avenue Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avenue Therapeutics' market value can be influenced by many factors that don't directly affect Avenue Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avenue Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avenue Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avenue Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.